The increasing emergence of penicillin-resistant and multiresistant strains of Streptococcus pneumoniae may pose a problem in coming years. We therefore compared sparfloxacin, a new fluoroquinolone with improved potency against streptococci, with amoxicillin, the "gold standard" in this setting, and another fluoroquinolone, ciprofloxacin, in a mouse pneumonia model. Their efficacies against penicillin-susceptible (serotype 3), macrolide-resistant (serotype 1), penicillin-resistant (serotype 23), and multiresistant (serotype 6) S. pneumoniae strains were evaluated. Immunocompetent Swiss mice (serotypes 1 and 3) and leukopenic mice (serotypes 6 and 23) were infected by peroral tracheal delivery of 10' to 10' CFU. Subcutaneous injections of antibiotics were initiated at 6, 18, 48, or 72 h after infection (six injections at 12-h intervals). In the immunocompetent mice, 100%o survival was obtained with sparfloxacin (50 mg/kg) and amoxicillin (5 mg/kg) against both penicillin-susceptible and macrolide-resistant strains; ciprofloxacin gave signifcantly lower survival rates. Two to four injections of sparfloxacin completely cleared bacteria from lungs and blood; the most rapid eradication was achieved with amoxicillin. Sparfloxacin also fully protected leukopenic mice against penicillin-resistant strains. The dose of amoxicillin (50 mgkg) required to protect mice and eradicate penicillin-resistant and multiresistant strains was 10 times higher than that effective against penicillin-susceptible strains. The microbiological and pharmacokinetic properties of sparfloxacin (e.g., the time during which concentrations exceed the MIC of the test pathogen) accounted for its efficacy against susceptible and resistant strains of S. pneumoniae in this model. Sparfloxacin (AT-4140) is a new quinolone with a broad spectrum of activity against both gram-positive and gramnegative bacteria (10, 11). Its potency against gram-negative organisms is similar to that of ciprofloxacin and greater than that of ofloxacin, enoxacin, or norfloxacin. Against grampositive organisms, sparfloxacin is more potent than the other quinolones (15). Given orally (p.o.) sparfloxacin is highly effective against systemic infections due to Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, and Pseudomonas aeruginosa in mice and is more potent than the other quinolones (15). The pharmacokinetics of sparfloxacin result in good absorption following oral administration, good tissue penetration, and a long half-life in plasma and tissues (14) .
Sparfloxacin (AT-4140) is a new quinolone with a broad spectrum of activity against both gram-positive and gramnegative bacteria (10, 11) . Its potency against gram-negative organisms is similar to that of ciprofloxacin and greater than that of ofloxacin, enoxacin, or norfloxacin. Against grampositive organisms, sparfloxacin is more potent than the other quinolones (15) . Given orally (p.o.) sparfloxacin is highly effective against systemic infections due to Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, and Pseudomonas aeruginosa in mice and is more potent than the other quinolones (15) . The pharmacokinetics of sparfloxacin result in good absorption following oral administration, good tissue penetration, and a long half-life in plasma and tissues (14) .
Streptococcus pneumoniae remains the leading cause of community-acquired pneumonia (12) . In addition, there is an increasing emergence of respiratory tract pathogens resistant to the most widely used drugs, i.e., penicillin G and macrolides (3, 9) . We therefore compared the efficacy of sparfloxacin with that of another fluoroquinolone, ciprofloxacin, in acute and subacute mouse models of S. pneumoniae pneumonia induced by penicillin-susceptible (P ), penicillinresistant (PR), macrolide-resistant (M ), and multiresistant S. pneumoniae strains. Animal survival, bacterial clearance from lungs, and pharmacokinetic data in both noninfected and infected mice were used to evaluate the feasibility of reducing the sparfloxacin treatment period. Blood samples were centrifuged to isolate serum, pooled (n = 6) each time, and frozen at -80°C until assay. Lungs were harvested from exsanguinated mice, washed in sterile sodium chloride solution, and frozen. On the day of the assay, organs were weighed, pooled (n = 6), and homogenized in phosphate buffer (pH 6.8). Homogenates were centrifuged, and supernatants were used for the assay. Antibiotic activities were determined by means of the agar well diffusion method using E. coli as the bioassay organism and Antibiotic Medium 1 (Difco Laboratories, Detroit, Mich.) as the growth medium. Standard solutions of sparfloxacin and ciprofloxacin were made in phosphate buffer (pH 6.8) for serum and tissue determinations in order to evaluate the active fractions of the antibiotics. Results were expressed as micrograms per milliliter or per gram of lung tissue. The standard curve was linear from 0.125 to 32 p,g/ml. The sensitivity of the assay was about 0.1 p,g/ml of sample, and the coefficient of between-and within-day variations for replicates (n = 5) was <7.5%.
Pharmacokinetic analysis. Concentration-time data were fitted to one-or two-compartment open models according to (Fig. 1A) , the survival rates with sparfloxacin (50 mg/kg p.o.) and amoxicillin (5 mg/kg s.c.) were 100% compared with about 50% with ciprofloxacin (100 mg/kg s.c.). When treatment was initiated at 18 h after infection (Fig.  1B) , sparfloxacin at 50 mg/kg was significantly more effective (80% survival) than ciprofloxacin at 100 mg/kg (23%) and 250 mg/kg (50%).
Results with the MR strain P 6254 were as follows. When treatments were initiated early, at 6 h p.i., sparfloxacin and ciprofloxacin similarly protected the animals. When treatments were delayed until 18 h after infection, sparfloxacin (50 mg/kg; six administrations) showed greater efficacy (80% survival) than ciprofloxacin at 100 mg/kg (40% survival).
In the subacute model (C57BL6 mice), survival rates with sparfloxacin (50 mg/kg) were the same (94%) when treatment b Number of animals with positive blood cultures/total number of animals.
c Greater than in all treatment groups (P < 0.01 to 0.001). d Lower than values for ciprofloxacin (P < 0.05 to 0.001). ' The lower limit of detection was 2.6 log1o CFU/ml (4 x 102 CFUr/ml). (Fig. 2) .
(ii) Avirulent strains in leukopenic mice (Swiss mice). For pR strain 54 B, sparfloxacin (50 mg/kg; six administrations s.c. initiated at 6 h p.i.) protected all the animals. Amoxicillin gave 70% protection at 50 mg/kg, a dosage 10 times higher than that effective against the Ps strain (Fig. 3) .
For multiresistant strains 170 B and Div 27, sparfloxacin (50 mg/kg; six s.c. administrations initiated at 6 h p.i.) gave 100% protection. In contrast, ciprofloxacin at the same dosage (50 mg/kg) gave only 7% protection, but there was 92% survival at 100 mg/kg. Amoxidcillin (50 mg/kg) gave 90% protection.
Bacterial clearance from lungs. In the acute model (Swiss mice), results with Ps strain P 4241 (Table 4) were as follows.
Six hours after a single s.c. injection of sparfloxacin and amoxicillin (50 mg/kg) or of ciprofloxacin (100 mg/kg), bacterial counts in the lungs were significantly lower than in controls. Twelve hours after a second antibiotic injection, bacteria were undetectable in the lungs of sparfloxacintreated animals, whereas counts in ciprofloxacin-treated animals were only 34% lower than in controls; sparfloxacin and amoxicillin were significantly more effective than ciprofloxacin. Bacteria were still detected in the lungs 12 h after six injections of ciprofloxacin. Blood from sparfloxacintreated mice was sterile 12 h after six injections, whereas blood from controls was not. Some animals treated with ciprofloxacin were bacteremic 12 h after the last injection.
For MR strain P 6254, four injections of sparfloxacin at 50 mg/kg each completely cleared bacteria from the lungs and blood, whereas five or six injections of ciprofloxacin at twice the dose (100 mg/kg) were necessary to clear the lungs.
In the subacute model (C57BV-6 mice), sparfloxacin completely cleared lungs and blood by 24 h after two injections. DISCUSSION Several studies have shown that sparfloxacin is at least as potent as ciprofloxacin against a wide spectrum of grampositive and gram-negative bacteria and is more active against S. pneunoniae (6, 10, 14, 15) . In contrast, results of few in vivo studies have been published. Nakamura et al. (15) found that oral sparfloxacin was highly effective against systemic infections with S. pneuwonwae and generally more active than ciprofloxacin. Bouanchaud et al. (4) found that sparfloxacin was more active than ofloxacin against three clinical isolates (Ms and MR strains) both in vitro and in mouse septicemia and pneumonia models on the basis of 50% effective doses. Our data support these results. Sparfloxacin at two-or fivefold-smaller doses than ciprofloxacin was more effective than this quinolone against a susceptible S. pneumoniae strain in the acute model of Swiss mice. Moreover, sparfloxacin remained effective late in the disease process when the lungs were severely inflamed and at a time when ciprofloxacin had lost all its activity, as shown in the subacute model. The efficacy of sparfloxacin in these models was similar to that previously reported for temafloxacin compared with ciprofloxacin and ofloxacin (1). These results were confirmed by using an MR strain.
Against pR and multiresistant strains, sparfloxacin was also highly effective. Increasing the dose of amoxicillin improved survival rates in animals infected with these pR pneumococci, in agreement with data reported by Pallares (17) , who found that pneumonia due to P pneumococci (0.1 < MIC <2 ,ug/ml) responded to intravenous high-dose penicillin therapy. Highly resistant S. pneumoniae strains (MIC, > 8 ,g/ml) might, however, require alternative antibiotic therapy, and a fluoroquinolone such as sparfloxacin could be effective.
The excellent activity of sparfloxacin in vivo is partly accounted for by the fact that its activity against grampositive organisms in vitro is generally higher than that of the other quinolones, but its pharmacokinetic behavior also appears to be involved. In both uninfected and infected mice given a single s.c. or p.o. dose of 50 mg/kg, the concentrations of sparfloxacin exceeded the MIC and the MBC for S. pneumoniae for up to 24 h, whereas at twice the dose, ciprofloxacin levels exceeded the MIC for 8 h and the MBC for no more than 2 h. These results are well correlated with pharmacokinetic data. Regardless of the route of administration, half-lives in serum and lung and the AUC of sparfloxacin in lung exceeded those of ciprofloxacin in healthy controls. These results are in agreement with those reported by Nakamura et al. (14) , who studied noninfected mice. Similar favorable pharmacokinetic behavior has also been found in healthy male volunteers (13) : following oral administration of 200 to 800 mg, peak levels in plasma (0.70 to 1.97 ,ug/ml) occurred at 4 to 5 h postdose; the mean tl2, for plasma ranged from 18 to 21 h, and AUCs for plasma ranged from 18 to 57 p,g. h/ml. We also found that the superior pharmacokinetics of sparfloxacin relative to ciprofloxacin were maintained in infected animals, and the prolonged residence times of sparfloxacin in the infected host could be another major determinant of its efficacy. This specific behavior was also previously reported for temafloxacin compared with ciprofloxacin and ofloxacin (1) and explains the greater efficacy of these new quinolones compared with ofloxacin and ciprofloxacin.
In conclusion, sparfloxacin, a new quinolone, is highly effective in a murine model of pneumonia induced by M5 and MR (P 6254) strains of S. pneumoniae as well as against multiresistant strains in immunocompromised animals. Clinical evaluation of this antibiotic as an alternative for patients with community-acquired pneumonia appears to be justified, as preliminary studies in humans suggest favorable pharmacokinetics. Indeed, Soejima et al. (18) found that sparfloxacin (300 mg once daily) was as effective as ofloxacin (200 mg three times daily) in the treatment of patients with bacterial pneumonia, and Hara et al. (8) have also reported that once-daily administration of sparfloxacin (300 mg) is as effective as ofloxacin (600 mg/day) for the treatment of chronic respiratory infections.
